StreetInsider.com News Articles

H.C. Wainwright Reiterates Buy Rating on ProMIS Neurosciences (PMN)

Wed, 15 Jul 2026 07:41:24 -0400

H.C. Wainwright analyst Raghuram Selvaraju reiterated a Buy rating and $18.00 price target on ProMIS Neurosciences (NASDAQ: PMN).

The analyst commented: "ProMIS Neurosciences yesterday announced the first human evidence of dose-dependent amyloid-beta oligomer (AβO) reduction by its lead Alzheimer’s disease (AD) drug candidate, PMN310, presented at AAIC 2026 in London, UK. The findings, drawn from analysis of samples collected during the company's Phase 1a trial in healthy volunteers, demonstrated that individuals receiving PMN310 exhibited a dose-dependent reduction in detectable AβO in cerebrospinal fluid (CSF) at both three and 29 days after dosing. While healthy individuals carry lower oligomer burdens than AD

ProMIS reports human evidence of PMN310 reducing amyloid-beta oligomers

Tue, 14 Jul 2026 05:50:13 -0400

ProMIS Neurosciences Inc. (Nasdaq: PMN) presented data at the 2026 Alzheimer's Association International Conference showing that its lead drug candidate, PMN310, produced a dose-dependent reduction of amyloid-beta oligomers (AβO) in human cerebrospinal fluid following a single dose in healthy volunteers.

The findings come from analysis of samples collected during the company's Phase 1a trial (NCT06105528). Participants receiving PMN310 showed reduced detectable AβO levels in cerebrospinal fluid at both three and 29 days after dosing. The company described this as one of the first quantitative demonstrations of treatment-related oligomer reduction in humans.

The oligomer measurements were conducted using surface-based fluorescence intensity distribution analysis

ProMIS reports human evidence of PMN310 reducing amyloid-beta oligomers

Tue, 14 Jul 2026 05:50:13 -0400

The oligomer measurements were conducted using surface-based fluorescence intensity distribution analysis

ProMIS Neurosciences Reports First Human Evidence of Amyloid-Beta Oligomer Target Engagement by PMN310 at AAIC 2026

Tue, 14 Jul 2026 02:30:00 -0400

PMN310 demonstrated dose-dependent reduction of amyloid-beta oligomers in human cerebrospinal fluid following a single dose in healthy volunteers

Represents one of the first quantitative measures of treatment-related effects on oligomer levels in a clinical trial

Company on track to present six-month blinded interim data from its Phase 1b trial in the coming weeks

Poster to be presented today, July 14, at the 2026 Alzheimer’s Association International Conference® (AAIC)

Cambridge, Massachusetts, July 14, 2026 (GLOBE NEWSWIRE) --

ProMIS Neurosciences Reports First Human Evidence of Amyloid-Beta Oligomer Target Engagement by PMN310 at AAIC 2026

Tue, 14 Jul 2026 02:30:00 -0400

PMN310 demonstrated dose-dependent reduction of amyloid-beta oligomers in human cerebrospinal fluid following a single dose in healthy volunteers

Represents one of the first quantitative measures of treatment-related effects on oligomer levels in a clinical trial

Company on track to present six-month blinded interim data from its Phase 1b trial in the coming weeks

Poster to be presented today, July 14, at the 2026 Alzheimer’s Association International Conference® (AAIC)

Cambridge, Massachusetts, July 14, 2026 (GLOBE NEWSWIRE) --

Roth/MKM Starts ProMIS Neurosciences (PMN) at Buy

Tue, 07 Jul 2026 16:12:53 -0400

Roth/MKM analyst Boobalan Pachaiyappan initiates coverage on ProMIS Neurosciences (NASDAQ: PMN) with a Buy rating and a price target of $19.00.
For an analyst ratings summary and ratings history on ProMIS Neurosciences click here. For more ratings news on ProMIS Neurosciences click here.
Shares of ProMIS Neurosciences closed at $13.71 yesterday.

Cantor Fitzgerald Starts ProMIS Neurosciences (PMN) at Overweight

Mon, 29 Jun 2026 16:44:58 -0400

Cantor Fitzgerald analyst Pete Stavropoulos initiates coverage on ProMIS Neurosciences (NASDAQ: PMN) with a Overweight rating.
For an analyst ratings summary and ratings history on ProMIS Neurosciences click here. For more ratings news on ProMIS Neurosciences click here.
Shares of ProMIS Neurosciences closed at $10.53 yesterday.

H.C. Wainwright Reiterates Buy Rating on ProMIS Neurosciences (PMN)

Wed, 24 Jun 2026 06:47:04 -0400

H.C. Wainwright analyst Raghuram Selvaraju reiterated a Buy rating and $18.00 price target on ProMIS Neurosciences (NASDAQ: PMN).
The analyst commented: "We recently hosted a corporate presentation by ProMIS Neurosciences management at our 7th Annual H.C. Wainwright & Co. Neuro Perspectives Conference. During the presentation, the company disclosed that it is planning to develop a subcutaneous formulation of PMN310, which we believe could provide a key convenience advantage vs. existing anti-amyloid antibodies—these agents all must be administered intravenously. Preparation is already underway for a single registrational Phase 3 study of PMN310, pending positive Phase 1b results. Preclinical advancement of amyotrophic lateral

H.C. Wainwright Reiterates Buy Rating on ProMIS Neurosciences (PMN)

Tue, 09 Jun 2026 06:48:11 -0400

H.C. Wainwright analyst Raghuram Selvaraju reiterated a Buy rating and $18.00 price target on ProMIS Neurosciences (NASDAQ: PMN).
The analyst commented: "We remind investors that the company’s ongoing Phase 1b trial, PRECISE-AD, reached full enrollment in December 2025—exceeding the company’s target of 128 subjects with a total of 144 patients enrolled—and is now approaching the six-month time point. The upcoming blinded interim data analysis anticipated early in 3Q26 (i.e., next quarter, or within the coming weeks) will summarize aggregate safety data and overall trends in key biomarkers across all study participants, without revealing treatment assignments. Since the analysis pools active and

Form S-8 ProMIS Neurosciences

Fri, 29 May 2026 16:17:00 -0400
si-local-file:///var/storage/secattach/20260529/26575404.html

Form S-8 ProMIS Neurosciences

Fri, 29 May 2026 16:17:00 -0400
si-local-file:///var/storage/secattach/20260529/26575404.html

ProMIS Neurosciences to Participate in Upcoming Conferences in June

Thu, 28 May 2026 10:13:00 -0400

CAMBRIDGE, Mass., May 28, 2026 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN), a clinical-stage biotechnology company developing antibody therapeutics and vaccines targeting toxic misfolded proteins in neurodegenerative diseases, today announced that it will participate in upcoming June 2026 conferences, and will be available for one-on-one meetings.

Conference details below:

Jefferies Global Healthcare Conference, June 2-4, 2026
Location: New York, NY
Presentation: Thursday, June 4, 2026, from 11:40 a.m. to 12:10 p.m. ET
Webcast link: Click here.

Virtual Alzheimer’s R&D Day, organized by Wolfe Research, June 4, 2026
Presentation: Thursday, June 4, 2026, from

ProMIS Neurosciences to Participate in Upcoming Conferences in June

Thu, 28 May 2026 10:13:00 -0400

CAMBRIDGE, Mass., May 28, 2026 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN), a clinical-stage biotechnology company developing antibody therapeutics and vaccines targeting toxic misfolded proteins in neurodegenerative diseases, today announced that it will participate in upcoming June 2026 conferences, and will be available for one-on-one meetings.

Conference details below:

Jefferies Global Healthcare Conference, June 2-4, 2026
Location: New York, NY
Presentation: Thursday, June 4, 2026, from 11:40 a.m. to 12:10 p.m. ET
Webcast link: Click here.

Virtual Alzheimer’s R&D Day, organized by Wolfe Research, June 4, 2026
Presentation: Thursday, June 4, 2026, from

ProMIS Neurosciences to Participate in Upcoming Conferences in June

Thu, 28 May 2026 10:13:00 -0400

CAMBRIDGE, Mass., May 28, 2026 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN), a clinical-stage biotechnology company developing antibody therapeutics and vaccines targeting toxic misfolded proteins in neurodegenerative diseases, today announced that it will participate in upcoming June 2026 conferences, and will be available for one-on-one meetings.

Conference details below:

Jefferies Global Healthcare Conference, June 2-4, 2026
Location: New York, NY
Presentation: Thursday, June 4, 2026, from 11:40 a.m. to 12:10 p.m. ET
Webcast link: Click here.

Virtual Alzheimer’s R&D Day, organized by Wolfe Research, June 4, 2026
Presentation: Thursday, June 4, 2026, from

ProMIS Neurosciences to Participate in Upcoming Conferences in June

Thu, 28 May 2026 10:13:00 -0400

CAMBRIDGE, Mass., May 28, 2026 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN), a clinical-stage biotechnology company developing antibody therapeutics and vaccines targeting toxic misfolded proteins in neurodegenerative diseases, today announced that it will participate in upcoming June 2026 conferences, and will be available for one-on-one meetings.

Conference details below:

Jefferies Global Healthcare Conference, June 2-4, 2026
Location: New York, NY
Presentation: Thursday, June 4, 2026, from 11:40 a.m. to 12:10 p.m. ET
Webcast link: Click here.

Virtual Alzheimer’s R&D Day, organized by Wolfe Research, June 4, 2026
Presentation: Thursday, June 4, 2026, from

ProMIS Neurosciences to Participate in Upcoming Conferences in June

Thu, 28 May 2026 10:13:00 -0400

CAMBRIDGE, Mass., May 28, 2026 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN), a clinical-stage biotechnology company developing antibody therapeutics and vaccines targeting toxic misfolded proteins in neurodegenerative diseases, today announced that it will participate in upcoming June 2026 conferences, and will be available for one-on-one meetings.

Conference details below:

Jefferies Global Healthcare Conference, June 2-4, 2026
Location: New York, NY
Presentation: Thursday, June 4, 2026, from 11:40 a.m. to 12:10 p.m. ET
Webcast link: Click here.

Virtual Alzheimer’s R&D Day, organized by Wolfe Research, June 4, 2026
Presentation: Thursday, June 4, 2026, from

ProMIS Neurosciences to Participate in Upcoming Conferences in June

Thu, 28 May 2026 10:13:00 -0400

CAMBRIDGE, Mass., May 28, 2026 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN), a clinical-stage biotechnology company developing antibody therapeutics and vaccines targeting toxic misfolded proteins in neurodegenerative diseases, today announced that it will participate in upcoming June 2026 conferences, and will be available for one-on-one meetings.

Conference details below:

Jefferies Global Healthcare Conference, June 2-4, 2026
Location: New York, NY
Presentation: Thursday, June 4, 2026, from 11:40 a.m. to 12:10 p.m. ET
Webcast link: Click here.

Virtual Alzheimer’s R&D Day, organized by Wolfe Research, June 4, 2026
Presentation: Thursday, June 4, 2026, from

ProMIS Neurosciences to Participate in Upcoming Conferences in June

Thu, 28 May 2026 10:13:00 -0400

CAMBRIDGE, Mass., May 28, 2026 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN), a clinical-stage biotechnology company developing antibody therapeutics and vaccines targeting toxic misfolded proteins in neurodegenerative diseases, today announced that it will participate in upcoming June 2026 conferences, and will be available for one-on-one meetings.

Conference details below:

Jefferies Global Healthcare Conference, June 2-4, 2026
Location: New York, NY
Presentation: Thursday, June 4, 2026, from 11:40 a.m. to 12:10 p.m. ET
Webcast link: Click here.

Virtual Alzheimer’s R&D Day, organized by Wolfe Research, June 4, 2026
Presentation: Thursday, June 4, 2026, from

ProMIS Neurosciences to Participate in Upcoming Conferences in June

Thu, 28 May 2026 10:13:00 -0400

CAMBRIDGE, Mass., May 28, 2026 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN), a clinical-stage biotechnology company developing antibody therapeutics and vaccines targeting toxic misfolded proteins in neurodegenerative diseases, today announced that it will participate in upcoming June 2026 conferences, and will be available for one-on-one meetings.

Conference details below:

Jefferies Global Healthcare Conference, June 2-4, 2026
Location: New York, NY
Presentation: Thursday, June 4, 2026, from 11:40 a.m. to 12:10 p.m. ET
Webcast link: Click here.

Virtual Alzheimer’s R&D Day, organized by Wolfe Research, June 4, 2026
Presentation: Thursday, June 4, 2026, from

Form 4 ProMIS Neurosciences For: May 20 Filed by: WYMAN WILLIAM W

Fri, 22 May 2026 16:36:00 -0400
si-local-file:///var/storage/secattach/20260522/26542418.html

Form 4 ProMIS Neurosciences For: May 20 Filed by: WYMAN WILLIAM W

Fri, 22 May 2026 16:36:00 -0400
si-local-file:///var/storage/secattach/20260522/26542418.html

Form 4 ProMIS Neurosciences For: May 20 Filed by: Warma Neil K

Fri, 22 May 2026 16:35:00 -0400
si-local-file:///var/storage/secattach/20260522/26542375.html

Form 4 ProMIS Neurosciences For: May 20 Filed by: Warma Neil K

Fri, 22 May 2026 16:35:00 -0400
si-local-file:///var/storage/secattach/20260522/26542375.html

Form 4 ProMIS Neurosciences For: May 20 Filed by: Williams Eugene

Fri, 22 May 2026 16:35:00 -0400
si-local-file:///var/storage/secattach/20260522/26542400.html

Form 4 ProMIS Neurosciences For: May 20 Filed by: Williams Eugene

Fri, 22 May 2026 16:35:00 -0400
si-local-file:///var/storage/secattach/20260522/26542400.html